Clinical trials: Depressive Symptoms
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Anxiety Disorders, Depressive Disorder
Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations
The prevalence of mental health problems among college populations has risen steadily in recent decades, with one third of today's students struggling with anxiety, depression, or an eating disorder (ED).
- Conditions
- Anxiety Disorders, Depressive Disorder, Eating Disorders
- Trial name
- iAIM EDU (NCT04162847)
- Testing
- SilverCloud Health Intervention
- Where
- 4 sites in United States
- Volunteers
- 6,205 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric…
- Trial name
- NCT00404755
- Testing
- escitalopram, bupropion, imipramine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Evaluation of a Mental Health Physician Support Program in Nova Scotia
The aim of this study is to test the program's effectiveness in a primary care setting in reducing stigma among medical personnel, increasing the comfort level of physicians and staff in providing care to those living with mental…
- Trial name
- NCT01975948
- Testing
- Mental Health Practice Support Program, Treatment as Usual
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- Nova Scotia Health Authority
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Cardiac Failure, Heart Failure
Insomnia Self-Management in Heart Failure
Chronic insomnia may contribute to the development and exacerbation of heart failure (HF), incident mortality and contributes to common and disabling symptoms (fatigue, dyspnea, anxiety, depression, excessive daytime sleepiness…
- Conditions
- Cardiac Failure, Heart Failure, Congestive Heart Failure, Heart Failure, Congestive
- Trial name
- HSS (NCT02660385)
- Testing
- Cognitive Behavioral Therapy for Insomnia, Self-Management Education for Heart Failure
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Yale University
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Symptoms of Depression and Anxiety
Mindfulness Intervention Using Virtual Reality in Older Adults With Symptoms of Anxiety and Depression in Ecuador
The availability of affordable hardware and rapidly growing content that can be freely accessed in the public domain raises the possibility of VR being used across the world globally and, in a very broad range of settings…
- Trial name
- NCT06219642
- Testing
- Mindfulness using virtual reality
- Where
- Ecuador
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Universidad San Francisco de Quito
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Major Depressive Disorder, MDD
Transcranial Alternating Current Stimulation for Major Depressive Disorder
Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on patients with Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT02339285)
- Testing
- tACS (alpha), tACS (gamma)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.
- Trial name
- NCT00101452
- Testing
- S-adenosyl-l-methionine, Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 199 people
- Sponsor
- Maurizio Fava, MD
Depressive Symptoms, Burden
Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study
The primary research question is which of the 2 best known dementia caregiver interventions, the New York University Caregiver intervention (NYUCI) and Resources for Enhancing Caregivers Health Offering Useful Treatments (REACH…
- Trial name
- NHiCE (NCT02092987)
- Testing
- Social work support, Educational material, NYU caregiver counseling intervention
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Columbia University
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Depression
Effects of Testosterone in Women With Depression
The purpose of the study is to determine whether adding a low dose of testosterone to current antidepressant therapy improves depression and fatigue in women who remain depressed despite necessary adequate doses of…
- Trial name
- NCT00676676
- Testing
- Testosterone
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital